SAGIMET BIOSCIENCES INC

SGMT stock update: Sagimet Biosciences rises 2.6% as it starts its U.S. Phase 3 denifanstat acne trial, with market cap $705 M and promising 2027 topline.

SGMT stock climbs 2.57%, driven by Phase 3 AURORA trial of denifanstat for severe acne—first patient dosed, top‑line data expected 2H 2027.

SGMT stocks surge 9.93%, driven by strong NASH pipeline and global reach; investors eye FDA updates & pharma partnerships for next growth wave.